TC Biopharm Announces Closing of $4 Million Underwritten Public Offering

Rhea-AI Summary

TC Biopharm (NASDAQ: TCBP) announced the closure of its underwritten public offering of 10 million American Depositary Shares (ADSs) at $0.40 each, generating gross proceeds of $4 million. The offering allows underwriters a 45-day option to purchase an additional 1.5 million ADSs. This funding is intended to support the development of gamma-delta T cell therapies for cancer. The company is recognized as a leader in this field and is conducting phase II/III clinical trials for its OmnImmune® treatment in acute myeloid leukemia.

Positive

• Successfully raised $4 million from the public offering.
• The company is advancing clinical trials for its innovative therapies.

Negative

• Potential dilution of existing shareholders due to the offering.
• Shares priced significantly lower than previous market prices.

EDINBURGH, Scotland, June 7, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer indications, today announced the closing of its previously announced underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

EF Hutton, division of Benchmark Investments, LLC, acted as sole book-running manager for the offering.

A registration statement on Form F-1 (File No. 333-265159), was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June 2, 2022. A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained from EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About TC Biopharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting an investigator-initiated clinical trial for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm is also building a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.

Forward-Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-closing-of-4-million-underwritten-public-offering-301563330.html

SOURCE TC BioPharm

FAQ

What was the purpose of the public offering by TC Biopharm (TCBP)?

The public offering aimed to raise funds to support the development of gamma-delta T cell therapies for cancer.

How much did TC Biopharm (TCBP) raise in its public offering?

TC Biopharm raised $4 million from the offering of 10 million ADSs.

What is the significance of the ADS pricing in TC Biopharm's public offering?

The ADSs were priced at $0.40 each, which could indicate investor valuation concerns.

Did TC Biopharm grant any options to its underwriters?

Yes, TC Biopharm granted underwriters a 45-day option to purchase an additional 1.5 million ADSs.